Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML
Clinical trial NCT03258931 · COMPLETED
Trial details
- NCT number
- NCT03258931
- Sponsor
- Arog Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-15
- Primary completion
- 2026-04-06
- Enrollment
- 214
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.